Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension

 
• By Ayisha Sharma
Red blood cells
Resistant Hypertension Patients Often Have Other Comorbidities • Source: Shutterstock

More from Clinical Trials

More from R&D